Home/Curadel Pharma/John Brimacombe
JB

John Brimacombe

President

Curadel Pharma

Therapeutic Areas

Curadel Pharma Pipeline

DrugIndicationPhase
ZW800-1 (nizaracianine triflutate)Ureter visualization during abdominopelvic surgeryPhase 3
Audacious Alpha TAT ProgramsMetastatic cancers (pan-tumor focus)Preclinical/Early Clinical